Today: 7 February 2026
Subscribe
Browse Category

Cancer Research News 16 January 2026 - 5 February 2026

TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics shares surged nearly 19% Thursday after the company filed an amended IND application for a Phase 2a trial of TTX-MC138 in colorectal cancer patients. Trading volume hit 11.5 million shares, up from 8,500 the previous day. The dose-expansion study, set to begin in early 2026, will enroll up to 45 patients with positive ctDNA markers. The trial will run with Quantum Leap Healthcare Collaborative on the PRE-I-SPY platform.
5 February 2026
····
Carnegie Mellon’s at-home cancer test draws $26.7m ARPA-H backing as AI courseware and leadership programs kick off 2026

Carnegie Mellon’s at-home cancer test draws $26.7m ARPA-H backing as AI courseware and leadership programs kick off 2026

Carnegie Mellon University secured up to $26.7 million in federal funding for an at-home test to detect over 30 types of Stage 1 cancer. Learnvia, backed by the Gates Foundation, will pilot AI-driven math courseware at 38 colleges this spring. TALI and Carnegie Mellon launched a six-month Emerging Leaders cohort for 29 professionals, set to graduate in June.
3 February 2026
·
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·······
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.
23 January 2026
·······
ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio shares rose 2.7% to $7.54 Friday after updated Phase 2 data showed 19 of 23 glioblastoma patients still alive, with median overall survival unreached. Over 31 million shares traded as investors awaited more trial details at a Jan. 31 summit. The company reported 2025 ANKTIVA revenue of $113 million and year-end cash of $242.8 million. The stock has tripled in three weeks.
23 January 2026
·····
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna shares held steady at $49.81 premarket Thursday after surging 15.8% on five-year melanoma data for its cancer vaccine with Merck. The vaccine-Keytruda combo cut recurrence or death risk by 49% versus Keytruda alone. U.S. vaccine-policy uncertainty is adding risk for the sector. Investors await Moderna’s Feb. 13 earnings call for updates on oncology data and 2026 sales.
22 January 2026
······
Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly shares rose 3.6% to $1,078.52 Wednesday after the FDA granted Breakthrough Therapy designation to its ovarian cancer drug candidate, sofetabart mipitecan. The company will report fourth-quarter earnings on February 4. Director Juan R. Luciano disclosed acquiring about 15 shares through deferred board compensation.
21 January 2026
·····
ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio shares fell 5.9% to $6.10 premarket after announcing an FDA meeting on possible resubmission of its ANKTIVA bladder-cancer drug. The FDA previously rejected the application for BCG-unresponsive papillary disease and has now requested more data. ImmunityBio plans to submit the information within 30 days. The company cites long-term trial data showing a 58.2% 12-month disease-free survival rate.
21 January 2026
·····
Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck shares rose 0.6% to $109.45 Tuesday, defying a broad U.S. market selloff. Five-year data showed its personalized melanoma vaccine with Moderna cut recurrence or death risk by 49% in a Phase 2b trial. Investors await Phase 3 trial timing and Merck’s Feb. 3 earnings call for more details. The S&P 500 fell 2.06% and Nasdaq lost 2.39%.
21 January 2026
·······
Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly shares closed up 0.3% at $1,041.29 Tuesday and rose slightly after hours after the FDA granted Breakthrough Therapy status to its ovarian cancer drug candidate, sofetabart mipitecan. The designation targets adults with platinum-resistant ovarian cancer. Analyst Seamus Fernandez maintained a buy rating but trimmed his price target. Abivax’s CEO denied rumors of takeover talks with Lilly.
21 January 2026
·····
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

New York, Jan 16, 2026, 12:51 PM EST — Regular session ImmunityBio (IBRX.O) shares jumped about 35% on Friday after the cancer drugmaker reported faster enrollment and stronger interim results in a key bladder cancer study for its ANKTIVA therapy. The stock was up $1.39 at $5.34 by 12:51 p.m. EST after hitting $5.53, with about 133 million shares traded. The company said more than 85% of patients are enrolled in its QUILT-2.005 trial and it is targeting a U.S. filing by the end of 2026; an interim analysis showed 85% of patients on ANKTIVA plus BCG stayed in complete
16 January 2026
·····
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

New York, Jan 16, 2026, 10:16 EST — Regular session ImmunityBio shares surged roughly 16.5% to $4.60 Friday morning, building on a strong rally after the biotech reported better-than-expected sales momentum for its main cancer drug. The company also detailed plans for a label-expansion effort. Trading volume exceeded 56 million shares, with the stock reaching an intraday peak of $5.20. This move is crucial as ImmunityBio aims to show its commercial potential goes beyond just clinical promise. Investors want clear evidence that ANKTIVA’s launch is picking up steam and that regulators might expand approvals beyond its current U.S. bladder cancer
16 January 2026
·····
1 2 3 … 6

Stock Market Today

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

7 February 2026
Singapore, February 7, 2026, 15:11 SGT — Market closed. Shares of Singapore’s Keppel Ltd (SGX:BN4) ended Friday at S$11.64, up 0.17%, with the market shut for the weekend and traders eyeing whether the post-results bid carries into Monday. A filing showed Keppel bought back 151,400 shares on Feb. 6 at prices between S$11.38 and S$11.55, spending about S$1.74 million including costs. (ShareInvestor) The stock had surged 6.1% on Thursday to close at S$11.62 after Keppel reported higher FY2025 earnings and laid out a larger distribution, sending the counter to its highest level in more than 12 years. That move did
ST Engineering stock price drops 2% to S$9.71 as drone-autonomy tie-up grabs attention

ST Engineering stock price drops 2% to S$9.71 as drone-autonomy tie-up grabs attention

7 February 2026
ST Engineering shares fell 1.9% to S$9.71 Friday, outpacing the Singapore market’s 0.8% drop amid a tech-led selloff. The company signed a deal with Shield AI at the Singapore Airshow to integrate autonomy software into its unmanned platforms and unveiled a small drone capable of carrying explosives. About 6.9 million shares traded as investors await full-year results on Feb. 27.
Go toTop